Venture Valuation Strengthens Advisory Board

Gamil G. de Chadarevian, Vice Chairman of the Board of Antigenics Inc. (NASDAQ: AGEN) has recently joined the advisory Board of Venture Valuation, Switzerland. He will advise and support the company on its expansion of the Biotech and Life Sciences Company Database "Biotechgate" in Europe and Venture Valuations assessment and valuation services.

Zurich, April 2005 - With the addition of Gamil G. de Chadarevian, Venture Valuation strengthens its Biotechnology and Life Sciences focus even more. Mr. de Chadarevian will provide his network and knowledge to extend Venture Valuations Biotechgate Company Database (www.biotechgate.com), an extended company directory of European companies in the biotechnology and life sciences field. Current featured countries include Austria (www.austrianbiotech.com), France (www.frenchbiotech.com), Italy (www.italianbiotech.com) and Switzerland (www.swisslifesciences.com). Mr de Chadarevian was very instrumental starting the Italian Biotech Database which was developed in cooperation with the governmental organization InvestinItaly. As a serial entrepreneur, investor, world citizen and biotechnology expert, Gamil G. de Chadarevian supports Venture Valuation also in the expansion of its independent, third party valuations. He is on the Advisory Board of Venture Valuation along with Dr. Christian Suter, formerly Director of Research and Development of Hoffmann-LaRoche's Vitamin Division and Prof. Cuno PĆ¼mpin, Extraordinarius for management at the University of St. Gallen, entrepreneur and also on the Advisory Board of Invision and The Blackstone Group.

About Gamil G. de Chadarevian Gamil G. de Chadarevian has served as Vice Chairman of the Board since 1995 and as Executive Vice President International from 1998 to 2001 of Antigenics Inc. (NASDAQ: AEGN).

Until April 1998, Mr. de Chadarevian was Managing Director of Special Projects at Alza International and the Vice President of Corporate Development for Corange London Limited, two pharmaceutical companies. Prior to 1992, he held positions at Pasfin Servizi Finanziara SpA, GEA Consulenza and Credit Suisse.

Mr. de Chadarevian is the founder and Lead Director of OphthalmoPharma Ltd. and a co-founder of Ikonisys Inc. and CambriaTech Holding SA. He serves on the advisory board of Syntek Capital AG and is a non-executive board member of Friends of San Patrignano, Inc., a charitable organization. In Italy he is an advisor for biotechnology to Sviluppo Italia, a government agency dedicated to promoting inward investment opportunities, and to Lay Line Genomics SpA, a biotechnology company.

Mr. de Chadarevian received his degree from the University of Zurich in Switzerland.

About Venture Valuation Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of proprietary software (www.venformis.com) and independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Germany, Canada and South Korea, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries. Further more, Venture Valuation has initiated, maintains and further develops the Biotech and Life Sciences Databases Biotechgate (www.biotechgate.com)

For further information, please contact: Venture Valuation AG Patrik Frei, CEO patrik.frei@venturevaluation.ch

Badenerstrasse 18 8004 Zurich Switzerland

Tel. +41 (43) 321 86 60 Fax +41 (43) 321 86 61

www.venturevaluation.com

Austrian Biotech Database www.austrianbiotech.com, French Biotech Database www.frenchbiotech.com Italian Biotech Database www.italianbiotech.com Swiss Biotech Database www.swisslifesciences.com European / Global Biotech Database www.biotechgate.com

Back to news